Market Cap
$825.5M
DNA
Ginkgo Bioworks Holdings, Inc.
$12.10 ▼ -3.16%
Prev close $12.50Market cap$825.5M
ConsensusStrong Sell
12-mo target$7.00 (-42.2%)
▼ Bearish
Analyst conviction 1/10
Insider Selling Cluster (4 insiders)27 New Institutional Positions10 Institutional Exits Genomics & Gene Editing
Snapshot
The big-picture read on DNA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Sell (0%)
Inst. Holders
50 funds
Inst. Value
$298.7M
Inst. Activity
27 buys / 10 sells
Insider Activity
$0.00 buy / $3.6M sell
Insider Net $
-$3.6M
Social Sentiment
53° Neutral
SEC Reports
3
Price chart 30d +72.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Sep 15, 2026 SEC Short Volume: DNA — 65.4% short (1.5M / 2.2M)
Short: 1,462,376 | Exempt: 527 | TRF Vol: 2,236,909 | Short Ratio: 65.4% | Off-exchange volume (dark
Director Christian O. Henry filed a Form 144 notice to sell 5,000 Class A shares (~$35,406 at ~$7.08/sh), representing a
144 — Impact 2/10
Sep 15, 2026 Insider
HENRY CHRISTIAN O sold 5,000 shares
Director @ $7.08 ($35.4K)
Aug 24, 2026 Insider
Coen Steven P. sold 330 shares
See remarks @ $6.98 ($2.3K)
Aug 21, 2026 Insider
Coen Steven P. acquired via exercise 156 shares
See remarks
Jun 30, 2026 Inst.
Erste Asset Management GmbH — ADD
2,536,939 shares ($25.9M)
Jun 30, 2026 Inst.
Apr 20, 2026 SEC VANGUARD PORTFOLIO MANAGEMENT LLC — ADD
937,803 shares ($9.3M)
Four insiders, including executives and a 10% owner, sold $2.52M in shares over a 7-day period, with open-market sales a
CLUSTER — Impact 6/10
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
0% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 4, 2026 | BTIG | REITERATE | Sell | 53% |
| Aug 7, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 3 | 5 | 2 | 0% | |
| Aug 1, 2026 | 0 | 1 | 2 | 5 | 2 | 10% | |
| Jul 1, 2026 | 0 | 1 | 2 | 5 | 2 | 10% | |
| Jun 1, 2026 | 0 | 1 | 2 | 5 | 2 | 10% | |
| May 1, 2026 | 0 | 1 | 2 | 5 | 3 | 9% | |
| Apr 1, 2026 | 0 | 1 | 2 | 5 | 3 | 9% | |
| Mar 1, 2026 | 0 | 1 | 2 | 5 | 3 | 9% | |
| Feb 1, 2026 | 0 | 1 | 2 | 5 | 3 | 9% |
Price targets
Where 2 covering analysts think DNA trades over the next 12 months.
$7.00 -42.2% upside Strong Sell
Current$12.11 Low$5.00 Median$7.00 High$9.00 2 analysts
$5.00$9.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
53°
Neutral
BearishNeutralBullish
Recent posts
Two new independent studies add even* more support to $ACRV
▲ 1 · 💬 3· ⚡ 0.5
$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne
▲ 1 · 💬 2· ⚡ 0.5
Stocks to purchase for extending Moore's Law?
▲ 1 · 💬 5· ⚡ 0.5
Moderna and Merck’s melanoma vaccine success is a major confidence boost for investors
▲ 1 · 💬 5· ⚡ 0.5
Nike. Can’t go much lower. Might stay flat for a while. Can go much higher. Pays decent dividend meanwhile.
▲ 1 · 💬 15· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 1 neutral · avg impact 4.7/10.
NEUTRAL1442/10
Director Christian O. Henry filed a Form 144 notice to sell 5,000 Class A shares (~$35,406 at ~$7.08
Sep 15, 2026
BEARISHCLUSTER6/10
Four insiders, including executives and a 10% owner, sold $2.52M in shares over a 7-day period, with
Apr 20, 2026
BEARISHCLUSTER6/10
Three corporate insiders at Ginkgo Bioworks (DNA) conducted open-market share sales over a 7-day per
Apr 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
short_volume
Short Volume: DNA — 65.4% short (1.5M / 2.2M)
Short: 1,462,376 | Exempt: 527 | TRF Vol: 2,236,909 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: DNA — 65.3% short (1.6M / 2.4M)
Short: 1,550,866 | Exempt: 766 | TRF Vol: 2,375,278 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: DNA — 65.4% short (0.7M / 1.0M)
Short: 675,232 | Exempt: 5,765 | TRF Vol: 1,033,236 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: DNA — 60.4% short (1.3M / 2.1M)
Short: 1,258,092 | Exempt: 31,550 | TRF Vol: 2,084,026 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: DNA — 56.3% short (0.4M / 0.8M)
Short: 440,857 | Exempt: 0 | TRF Vol: 782,398 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.58 | $-0.58–$-0.58 | — | — | — | $0.0B | 1 |
| Next Q | $-0.82 | $-0.82–$-0.82 | 42.3% | — | — | $0.0B | 1 |
| Current FY | $-3.20 | $-3.20–$-3.20 | 12.5% | +6.4% | 1↑ 0↓ | $0.1B | 1 |
| Next FY | $-2.90 | $-2.90–$-2.90 | 9.4% | +9.7% | 1↑ 0↓ | $0.1B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.580 | — |
| 7d ago | $0.000 | -0.580 |
| 30d ago | $0.000 | -0.580 |
| 60d ago | $0.000 | -0.580 |
| 90d ago | $0.000 | -0.580 |
Institutional ownership
Which big funds own DNA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $298.7M total value (30,064,373 shares) as of 2026-Q2. Top holders: BlackRock,, VIKING, Erste. Net buying activity: 27 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 4,282,903 | $42.4M | 14.2% | — |
| VIKING GLOBAL INVESTORS LP | 3,577,128 | $35.4M | 11.9% | — |
| Erste Asset Management GmbH | 2,536,939 | $25.9M | 8.7% | ADD +30.3% |
| BAILLIE GIFFORD & CO | 2,391,649 | $23.7M | 7.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,087,293 | $20.7M | 6.9% | — |
| Legal & General Group Plc | 1,669,419 | $16.5M | 5.5% | — |
| STATE STREET CORP | 1,472,370 | $14.6M | 4.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,222,016 | $12.1M | 4.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 937,803 | $9.3M | 3.1% | ADD +65.8% |
| Allianz Asset Management GmbH | 785,798 | $7.8M | 2.6% | ADD +55.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | ADD | 1,947,728 | 2,536,939 | +30.3% | $25.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 565,652 | 937,803 | +65.8% | $9.3M |
| MILLENNIUM MANAGEMENT LLC | ADD | 487,957 | 638,676 | +30.9% | $6.3M |
| GOLDMAN SACHS GROUP INC | TRIM | 929,862 | 607,376 | -34.7% | $6.0M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 100,456 | 539,856 | +437.4% | $5.3M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 127,048 | 351,200 | +176.4% | $3.5M |
| TUDOR INVESTMENT CORP ET AL | TRIM | 464,663 | 335,710 | -27.8% | $3.3M |
| Bank of New York Mellon Corp | ADD | 123,959 | 170,481 | +37.5% | $1.7M |
| D. E. Shaw & Co., Inc. | DOUBLED | 27,169 | 151,356 | +457.1% | $1.5M |
| MORGAN STANLEY | TRIM | 460,000 | 144,314 | -68.6% | $1.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 49 transactions. Net -$3.6M — $0.00 bought, $3.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | HENRY CHRISTIAN O | Director | SELL | 5,000 | $7.08 | $35.4K |
| Aug 24, 2026 | Coen Steven P. | See remarks | SELL | 330 | $6.98 | $2.3K |
| Aug 21, 2026 | Coen Steven P. | See remarks | EXERCISE | 156 | — | — |
| Aug 21, 2026 | Coen Steven P. | See remarks | EXERCISE | 587 | — | — |
| Jul 28, 2026 | Canton Barry | 10%+ Owner | AWARD | 35,736 | — | — |
| Jul 28, 2026 | Shetty Reshma P. | See remarks | AWARD | 35,736 | — | — |
| Jul 28, 2026 | Canton Barry | 10%+ Owner | AWARD | 39,038 | — | — |
| Jul 28, 2026 | Canton Barry | 10%+ Owner | AWARD | 117,135 | — | — |
| Jul 28, 2026 | Shetty Reshma P. | See remarks | AWARD | 127,423 | — | — |
| Jul 28, 2026 | Kelly Jason R | See remarks | AWARD | 74,258 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DNA.
Shares short
7,166,128
Settlement Sep 15, 2026
Change vs prior
+4.4%
Semi-monthly cycle
Days to cover
7.2
At avg daily volume
Of shares outstanding
≈11.1%
Estimate — not % of float
All DNA filing & press-release reports (3)
- 144 reportSep 15, 2026
- CLUSTER reportApr 20, 2026
- CLUSTER reportApr 13, 2026